{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:00:47Z","timestamp":1784127647508,"version":"3.55.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T00:00:00Z","timestamp":1613952000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n            <jats:title>Background.<\/jats:title>\n            <jats:p>There are challenges in designing adequate, well-controlled studies of patients with active antibody-mediated rejection (AMR) after kidney transplantation (KTx).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods.<\/jats:title>\n            <jats:p>We assessed the functional relationship between change in estimated glomerular filtration rate (eGFR) following the diagnosis of AMR and the risk of subsequent death-censored graft failure using the joint modeling framework. We included recipients of solitary KTx between 1995 and 2013 at 4 transplant centers diagnosed with biopsy-proven active AMR at least 1 year post-KTx, who had a minimum of 3-year follow-up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results.<\/jats:title>\n            <jats:p>A total of 91 patients across participating centers were included in the analysis. Of the 91 patients, n = 54 patients (59%) met the death-censored graft failure endpoint and n = 62 patients (68%) met the all-cause graft failure composite endpoint. Kaplan-Meier death-censored graft survival rates at 12, 36, and 60 months postdiagnosis of AMR pooled across centers were 88.9%, 58.9%, and 36.4%, respectively. Spaghetti plots indicated a linear trend in the change in eGFR, especially in the first 12 months postdiagnosis of active AMR. A significant change in eGFR was observed within the first 12 months postdiagnosis of active AMR, getting worse by a factor of \u22120.757 mL\/min\/1.73 m<jats:sup>2<\/jats:sup> per month during the 12-month analysis period (a delta of \u22129.084 mL\/min\/1.73 m<jats:sup>2<\/jats:sup> at 1 y). Notably, an extrapolated 30% improvement in the slope of eGFR in the first 12 months was associated with a 10% improvement in death-censored graft failure at 5 years.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions.<\/jats:title>\n            <jats:p>If prospectively validated, this study may inform the design of pivotal clinical trials for therapies for late AMR.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/tp.0000000000003274","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T08:02:57Z","timestamp":1587628977000},"page":"648-659","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":36,"title":["Change in Estimated GFR and Risk of Allograft Failure in Patients Diagnosed With Late Active Antibody-mediated Rejection Following Kidney Transplantation"],"prefix":"10.1097","volume":"105","author":[{"given":"William","family":"Irish","sequence":"first","affiliation":[{"name":"Department of Surgery, Brody School of Medicine at East Carolina University, Greenville, NC."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nickerson","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad C.","family":"Astor","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Wisconsin, Madison, WI."},{"name":"Department of Population Health Sciences, University of Wisconsin, Madison, WI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Chong","sequence":"additional","affiliation":[{"name":"Vitaeris, Inc., Vancouver, BC, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Wiebe","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Manitoba, Winnipeg, MB, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Moreso","sequence":"additional","affiliation":[{"name":"University Hospital Vall d\u2019Hebron, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Seron","sequence":"additional","affiliation":[{"name":"University Hospital Vall d\u2019Hebron, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Crespo","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital del Mar, Institute Mar for Medical Research, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Gache","sequence":"additional","affiliation":[{"name":"CTI Consulting, Covington, KY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjang","family":"Djamali","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Wisconsin, Madison, WI."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,2,22]]},"reference":[{"key":"R1-20250604","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1600-6143.2010.03283.x","article-title":"Long-term renal allograft survival in the United States: a critical reappraisal.","volume":"11","author":"Lamb","year":"2011","journal-title":"Am J Transplant"},{"key":"R2-20250604","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","article-title":"Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence.","volume":"12","author":"Sellar\u00e9s","year":"2012","journal-title":"Am J Transplant"},{"key":"R3-20250604","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1600-6143.2008.02519.x","article-title":"Identifying specific causes of kidney allograft loss.","volume":"9","author":"El-Zoghby","year":"2009","journal-title":"Am J Transplant"},{"key":"R4-20250604","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/ajt.14625","article-title":"The Banff 2017 Kidney Meeting report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials.","volume":"18","author":"Haas","year":"2018","journal-title":"Am J Transplant"},{"key":"R5-20250604","doi-asserted-by":"crossref","first-page":"e94197","DOI":"10.1172\/jci.insight.94197","article-title":"Assessing rejection-related disease in kidney transplant biopsies based on archetypal analysis of molecular phenotypes.","volume":"2","author":"Reeve","year":"2017","journal-title":"JCI Insight"},{"key":"R6-20250604","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/ajt.12589","article-title":"Diagnosis and management of antibody-mediated rejection: current status and novel approaches.","volume":"14","author":"Djamali","year":"2014","journal-title":"Am J Transplant"},{"key":"R7-20250604","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.humimm.2016.01.018","article-title":"Current outcomes of chronic active antibody mediated rejection\u2014a large single center retrospective review using the updated BANFF 2013 criteria.","volume":"77","author":"Redfield","year":"2016","journal-title":"Hum Immunol"},{"key":"R8-20250604","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1111\/ajt.13347","article-title":"Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody.","volume":"15","author":"Wiebe","year":"2015","journal-title":"Am J Transplant"},{"key":"R9-20250604","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1111\/ajt.14520","article-title":"Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: a multicenter, prospective, randomized, double-blind clinical trial.","volume":"18","author":"Moreso","year":"2018","journal-title":"Am J Transplant"},{"key":"R10-20250604","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/ajt.14107","article-title":"The Banff 2015 Kidney meeting report: current challenges in rejection classification and prospects for adopting molecular pathology.","volume":"17","author":"Loupy","year":"2017","journal-title":"Am J Transplant"},{"key":"R11-20250604","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate.","volume":"145","author":"Levey","year":"2006","journal-title":"Ann Intern Med"},{"key":"R12-20250604","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.2215\/CJN.01640309","article-title":"Measurement and estimation of GFR in children and adolescents.","volume":"4","author":"Schwartz","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R13-20250604","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/01621459.1979.10481038","article-title":"Robust locally weighted regression and smoothing scatterplots.","volume":"74","author":"Cleveland","year":"1979","journal-title":"J Am Stat Assoc"},{"key":"R16-20250604","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1097\/TP.0b013e3182692b70","article-title":"Identification and characterization of kidney transplants with good glomerular filtration rate at 1 year but subsequent progressive loss of renal function.","volume":"94","author":"Park","year":"2012","journal-title":"Transplantation"},{"key":"R17-20250604","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1046\/j.1600-6135.2003.00275.x","article-title":"Poor predictive value of serum creatinine for renal allograft loss.","volume":"3","author":"Kaplan","year":"2003","journal-title":"Am J Transplant"},{"key":"R18-20250604","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1681\/ASN.2014040378","article-title":"Through a glass darkly: seeking clarity in preventing late kidney transplant failure.","volume":"26","author":"Stegall","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"R19-20250604","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1111\/tri.12806","article-title":"Intrapatient variability in tacrolimus exposure\u2014a useful tool for clinical practice?","volume":"29","author":"Knight","year":"2016","journal-title":"Transpl Int"},{"key":"R20-20250604","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1600-6143.2004.00386.x","article-title":"Biomarkers and surrogate endpoints in renal transplantation: present status and considerations for clinical trial design.","volume":"4","author":"Lachenbruch","year":"2004","journal-title":"Am J Transplant"},{"issue":"6 Suppl 1","key":"R21-20250604","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1053\/ajkd.1998.v31.pm9631863","article-title":"Proposed consensus for definitions and endpoints for clinical trials of acute kidney transplant rejection.","volume":"31","author":"Guttmann","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"R22-20250604","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1600-6143.2011.03525.x","article-title":"Summary of FDA antibody-mediated rejection workshop.","volume":"11","author":"Archdeacon","year":"2011","journal-title":"Am J Transplant"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003274","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T19:15:23Z","timestamp":1749064523000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000003274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,22]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000003274","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,22]]}}}